Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05256836
Other study ID # 2105-117-1220
Secondary ID
Status Suspended
Phase N/A
First received
Last updated
Start date February 7, 2022
Est. completion date December 2023

Study information

Verified date April 2023
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the effectiveness of tablet computer-based cognitive training in patients with idiopathic REM sleep behavior disorder.


Description:

Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by abnormal movement to reproduce dreams and loss of skeletal muscle tension during REM sleep. Idiopathic RBD (iRBD) refers to the absence of any predisposing factors or comorbid neurological disorders. iRBD is considered the prodromal stage of alpha-synucleinopathy. Through past studies, it has been confirmed that cognitive function decline has already occurred in a significant number of iRBD patients. However, there is still no treatment that can suppress or delay the onset of neurodegenerative diseases. The cognitive function improvement effect of computerized cognitive training in the elderly and patients with mild cognitive impairment is known. However, the effect of cognitive training on improving cognitive function in iRBD patients has not been studied. The investigators developed a program that allows patients to train cognitive functions in various domains by repeatedly performing tasks related to daily life activities. In addition, by loading the program on the tablet computer, it is possible to participate in the training easily at home using the touch screen without visiting the hospital.


Recruitment information / eligibility

Status Suspended
Enrollment 60
Est. completion date December 2023
Est. primary completion date August 2023
Accepts healthy volunteers No
Gender All
Age group 60 Years to 80 Years
Eligibility Inclusion Criteria: - Patients aged 60-80 years old who have been diagnosed with iRBD through nocturnal polysomnography according to the International Classification of Sleep Disorders 3rd Edition (ICSD-3) diagnostic criteria - Those who gave their written consent to participate in the study Exclusion Criteria: - Patients with neurodegenerative diseases including Parkinson's disease, dementia, and multiple system atrophy - Patients with secondary causes of RBD - Patients with severe hearing, visual impairment, or motor impairment - Patients who have received cognitive training within the last year

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Tablet computer-based cognitive training program
The subject of the study executes a program mounted on a tablet personal computer (PC) (Samsung Galaxy Tab S6 Lite) and performs a cognitive training task by touching the screen with the index finger. It consists of 10 tasks related to the activity of daily living: 1) taking medicine, 2) making a phone call, 3) taking a shower, 4) doing laundry, 5) finding directions, 6) riding the bus, 7) buying goods, 8) Money management, 9) ingredient sorting, 10) meal preparation. It is involved in cognitive functions in various domains such as attention, working memory, processing speed, problem solving, visuospatial ability, verbal and visuospatial memory. There are three levels of difficulty for each task, high, medium, and low, and the difficulty becomes more difficult as session 1 to 36 progresses. One cognitive training session lasts about 30 minutes.

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K) total score Z score of total 5 domains (attentive, memory, language, visuospatial and executive functions) Change from baseline CERAD-K total score at 12 weeks
Secondary Change in CERAD-K attention score Scores for each of the 5 domains
1.Attention
Trail making test A (0~360): higher scores mean a worse outcome
Stroop test (word) (0~): higher scores mean a better outcome
Change from baseline CERAD-K attention score at 12 weeks
Secondary Change in CERAD-K memory score Scores for each of the 5 domains 2.Memory
Word registration (0~30): higher scores mean a better outcome
Word recall (0~10): higher scores mean a better outcome
Word recognition (0~10): higher scores mean a better outcome
Constructional recall (0~11): higher scores mean a better outcome
Change from baseline CERAD-K memory score at 12 weeks
Secondary Change in CERAD-K language score Scores for each of the 5 domains 3.Language
- Boston naming test (0~15): higher scores mean a better outcome
Change from baseline CERAD-K language score at 12 weeks
Secondary Change in CERAD-K visuospatial function score Scores for each of the 5 domains 4.Visuospatial function
- Constructional behavior (0~11): higher scores mean a better outcome
Change from baseline CERAD-K visualspatial function score at 12 weeks
Secondary Change in CERAD-K executive function score Scores for each of the 5 domains 5.Executive function
Trail making test B (0~300): higher scores mean a worse outcome
Language fluency (0~): higher scores mean a better outcome
Stroop test (word/color) (0~): higher scores mean a better outcome
Change from baseline CERAD-K executive function score at 12 weeks
Secondary Change in mini-mental status examination in the Korean version (MMSE-K) score minimum value: 0, maximum value: 30 (higher scores mean a better outcome) Change from baseline MMSE-K score at 12 weeks
Secondary Change in Korean version of Montreal Cognitive Assessment (MoCA-K) score minimum value: 0, maximum value: 30 (higher scores mean a better outcome) Change from baseline MoCA-K score at 12 weeks
Secondary Change in resting electroencephalography (EEG) power spectrum distribution of power into frequency components composing the signal (delta, theta, alpha, beta) Change from baseline EEG power spectrum at 12 weeks
Secondary Change in resting electroencephalography (EEG) weighted phase lag index a functional connectivity measure that quantified how consistently 90° (or 270°) phase 'lagging' one EEG signal was compared to another (From 0 to 1, if it is close to 1, the connectivity is high) Change from baseline EEG weighted phase lag index at 12 weeks
Secondary Change in event-related potential (ERP) reaction time time (ms) from target presentation to button press Change from baseline ERP reaction time at 12 weeks
Secondary Change in event-related potential (ERP) hit rate the probability that an old item is either correctly recognized, or not Change from baseline ERP hit rate at 12 weeks
Secondary Change in event-related potential (ERP) N2 amplitude The N2 peak (µV) is a fronto-central maximal negativity observed approximately 150-400 ms after stimulus onset Change from baseline ERP N2 amplitude at 12 weeks
Secondary Change in event-related potential (ERP) time-frequency analysis Indicates the power of the EEG frequency at a specific time Change from baseline ERP time-frequency analysis at 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03671772 - Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the FDRs of Patients With RBD
Recruiting NCT05109364 - Terazosin and Parkinson's Disease Extension Study Phase 2
Recruiting NCT03288909 - Ultra High Field Magnetic Resonance Imaging as a Biomarker for Premotor Parkinson's Disease
Completed NCT04006925 - Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate Phase 4
Completed NCT03353207 - Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
Completed NCT02824341 - Exploration of the Reward System by Functional MRI in Parkinson's Disease Patients With and Without REM Sleep Behavior Disorder N/A
Recruiting NCT03671798 - Establish a National Registry of REM Sleep Behavior Disorder
Enrolling by invitation NCT01453127 - DaTSCAN Imaging in Aging and Neurodegenerative Disease Phase 4
Terminated NCT02871427 - Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Phase 2
Completed NCT03595475 - Prodromal Markers of First-degree Relatives of Patients With Psychiatric Disorders Comorbid With RBD
Recruiting NCT03660982 - Familial Aggregation and Biomarkers in REM Sleep Behaviour Disorder.
Completed NCT03255642 - Efficacy and Safety of Melatonin and Clonazepam for IRBD N/A
Recruiting NCT05904717 - Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder Phase 2
Not yet recruiting NCT06140511 - DREAMER - IsolateD REM Sleep Without Atonia as a Risk Factor for REM Sleep Behavior disordER
Recruiting NCT04386317 - Terazosin Effect on Cardiac Changes in Early Parkinson's Disease Phase 2
Enrolling by invitation NCT05514106 - MIBG in Aging and Neurologic Disorders Phase 4
Completed NCT03645226 - Gut Microbiota Across Early Stages of Synucleinopathy: From High-risk Relatives, REM Sleep Behavior Disorder to Early Parkinson's Disease
Recruiting NCT05262543 - PREdictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study
Recruiting NCT04071899 - French Validation of a Severity Scale in REM Sleep Behavior Disorder (SEV-TCSP)
Recruiting NCT04048603 - Search for Biomarkers of Neurodegenerative Diseases in Idiopathic REM Sleep Behavior Disorder